FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3207712949> ?p ?o ?g. }

• W3207712949 endingPage "S935" @default.
• W3207712949 startingPage "S935" @default.
• W3207712949 abstract "Care for older adults with cancer is complex as they often present with multiple comorbidities and polypharmacy, have poor performance status and limited social supports. These factors often lead to exclusion from standard therapy and clinical trials. In the past decade, treatment of NSCLC has changed due to novel therapeutics with improved tolerability due to lower adverse effect profile, leading to increased uptake of systemic therapy. The study goal is to compare the uptake of systemic therapy in adults with advanced NSCLC before and after the availability of targeted therapy and immunotherapy, and to examine the evolution in treatment patterns between younger and older adults. All patients with stage IV NSCLC referred to BC Cancer in 2009, 2011, 2015 and 2017 were included in the study. One-year time points were chosen based on molecular testing implementation and provincial formulary listing: baseline (2009), EGFR testing (2011), ALK testing (2015) and immunotherapy listing (2017). Age was categorized as younger (<70 years) and older (70+). Baseline demographics, disease characteristics and systemic therapy details (drug, duration, line of therapy) were collected retrospectively. Baseline characteristics will be compared by using descriptive statistics. Univariate analysis using the X2 and Fisher’s exact tests were used to compare age groups. Multivariate analysis was conducted using logistic-regression analysis. Table 1Comparison of systemic therapy uptake between adults <70 and 70+ years of age2009201120152017<70 (n=315)70+ (n=271)p-value<70 (n=437)70+ (n=366)p-value<70 (n=492)70+ (n=534)p-value<70 (n=484)70+ (n=522)p-valueSex Female Male148 (47%) 167 (53%)131 (48%) 140 (52%)0.80219 (50%) 218 (50%)175 (48%) 191 (52%)0.52265 (54%) 227 (46%)267 (50%) 267 (50%)0.24251 (52%) 233 (48%)245 (47%) 277 (53%)0.13ECOG Performance Statu at Diagnosis 0-1 2+ Unknown117 (37%) 173 (55%) 25 (8%)78 (29%) 168 (62%) 25 (9%)0.1187 (43%) 186 (43%) 64 (14%)106 (29%) 205 (56%) 55 (15%)<0.01185 (38%) 240 (49%) 67 (13%)137 (26%) 326 (61%) 71 (13%)<0.01169 (35%) 260 (54%) 55 (11%)122 (23%) 330 (63%) 70 (13%)<0.01Histology Non-Squamous Squamous NOS131 (42%) 33 (10%) 151 (48%)94 (35%) 52 (19%) 125 (46%)0.01285 (65%) 59 (14%) 93 (21%)215 (59%) 64 (17%) 87 (24%)0.14329 (67%) 73 (15%) 90 (18%)310 (58%) 83 (16%) 141 (26%)0.01312 (65%) 59 (12%) 113 (23%)311 (60%) 61 (12%) 150 (29%)0.15Treatment Type Best Supportive Care Chemotherapy only Any line targeted therapy Any line immunotherapy176 (56%) 136 (43%) 2 (0.6%) 1 (0.3%)210 (78%) 60 (22%) 1 (0.4%) 0<0.01206 (47%) 196 (45%) 33 (8%) 2 (0.5%)276 (75%) 66 (18%) 22 (6%) 2 (0.5%)<0.01244 (50%) 159 (32%) 65 (13%) 24 (5%)386 (72%) 95 (18%) 43 (8%) 10 (2%)<0.01234 (48%) 66 (14%) 88 (18%) 96 (20%)370 (71%) 46 (9%) 50 (10%) 56 (11%)<0.01Lines of Therapy No treatment 1 line of therapy 2 lines of therapy 3 or more lines of therapy176 (56%) 58 (18%) 43 (14%) 38 (12%)210 (78%) 29 (11%) 16 (6%) 16 (6%)<0.01206 (47%) 86 (20%) 74 (17%) 71 (16%)276 (75%) 44 (12%) 30 (8%) 16 (4%)<0.01244 (50%) 153 (31%) 56 (11%) 39 (8%)386 (72%) 99 (19%) 29 (5%) 20 (4%)<0.01234 (48%) 118 (24%) 81 (17%) 51 (11%)370 (71%) 97 (19%) 38 (7%) 17 (3%)<0.01Patients with EGFR mutation were 0.5%, 7%, 9%, and 12%; and ALK fusion were 0%, 0.1%, 2%, and 2% in 2009, 2011, 2015, and 2017 respectively. Open table in a new tab Table 2Multivariate analysis of the comparison of systemic therapy uptake between adults <70 and 70+ years of age; controlling for sex and ECOG performance status<70 years70+ yearsOR (95% CI)p-valueOR (95% CI)p-value2009 2011 2015 2017(Reference) 1.36 (1.00 – 1.86) 1.30 (0.96-1.76) 1.44 (1.06-1.95)0.05 0.09 0.02(Reference) 1.16 (0.78-1.72) 1.47 (1.03-2.12) 1.66 (1.16-2.40)0.46 0.37 0.01 Open table in a new tab Patients with EGFR mutation were 0.5%, 7%, 9%, and 12%; and ALK fusion were 0%, 0.1%, 2%, and 2% in 2009, 2011, 2015, and 2017 respectively. There has been an increased uptake of systemic therapy with the advent of novel therapeutics across all age groups. A significant proportion of older adults receive only best supportive care, likely influenced by poor performance status at presentation. With the introduction of new systemic therapy options including targeted and immunotherapy, more older adult patients are receiving treatment, narrowing the therapeutic gap with their younger cohort." @default.
• W3207712949 created "2021-10-25" @default.
• W3207712949 creator A5005881789 @default.
• W3207712949 creator A5006435743 @default.
• W3207712949 creator A5013840803 @default.
• W3207712949 creator A5031485296 @default.
• W3207712949 creator A5039554574 @default.
• W3207712949 creator A5039964937 @default.
• W3207712949 creator A5041626111 @default.
• W3207712949 creator A5051158367 @default.
• W3207712949 creator A5087049625 @default.
• W3207712949 date "2021-10-01" @default.
• W3207712949 modified "2023-10-18" @default.
• W3207712949 title "MA15.06 Real World Trends in Treatment Patterns for Patients With Advanced NSCLC: Comparing Changes Between Younger and Older Adults" @default.
• W3207712949 doi "https://doi.org/10.1016/j.jtho.2021.08.192" @default.
• W3207712949 hasPublicationYear "2021" @default.
• W3207712949 type Work @default.
• W3207712949 sameAs 3207712949 @default.
• W3207712949 citedByCount "0" @default.
• W3207712949 crossrefType "journal-article" @default.
• W3207712949 hasAuthorship W3207712949A5005881789 @default.
• W3207712949 hasAuthorship W3207712949A5006435743 @default.
• W3207712949 hasAuthorship W3207712949A5013840803 @default.
• W3207712949 hasAuthorship W3207712949A5031485296 @default.
• W3207712949 hasAuthorship W3207712949A5039554574 @default.
• W3207712949 hasAuthorship W3207712949A5039964937 @default.
• W3207712949 hasAuthorship W3207712949A5041626111 @default.
• W3207712949 hasAuthorship W3207712949A5051158367 @default.
• W3207712949 hasAuthorship W3207712949A5087049625 @default.
• W3207712949 hasBestOaLocation W32077129491 @default.
• W3207712949 hasConcept C100406419 @default.
• W3207712949 hasConcept C121608353 @default.
• W3207712949 hasConcept C126322002 @default.
• W3207712949 hasConcept C143998085 @default.
• W3207712949 hasConcept C144301174 @default.
• W3207712949 hasConcept C185926286 @default.
• W3207712949 hasConcept C197934379 @default.
• W3207712949 hasConcept C2776907518 @default.
• W3207712949 hasConcept C2778375690 @default.
• W3207712949 hasConcept C36434225 @default.
• W3207712949 hasConcept C38180746 @default.
• W3207712949 hasConcept C512399662 @default.
• W3207712949 hasConcept C530470458 @default.
• W3207712949 hasConcept C71924100 @default.
• W3207712949 hasConceptScore W3207712949C100406419 @default.
• W3207712949 hasConceptScore W3207712949C121608353 @default.
• W3207712949 hasConceptScore W3207712949C126322002 @default.
• W3207712949 hasConceptScore W3207712949C143998085 @default.
• W3207712949 hasConceptScore W3207712949C144301174 @default.
• W3207712949 hasConceptScore W3207712949C185926286 @default.
• W3207712949 hasConceptScore W3207712949C197934379 @default.
• W3207712949 hasConceptScore W3207712949C2776907518 @default.
• W3207712949 hasConceptScore W3207712949C2778375690 @default.
• W3207712949 hasConceptScore W3207712949C36434225 @default.
• W3207712949 hasConceptScore W3207712949C38180746 @default.
• W3207712949 hasConceptScore W3207712949C512399662 @default.
• W3207712949 hasConceptScore W3207712949C530470458 @default.
• W3207712949 hasConceptScore W3207712949C71924100 @default.
• W3207712949 hasIssue "10" @default.
• W3207712949 hasLocation W32077129491 @default.
• W3207712949 hasOpenAccess W3207712949 @default.
• W3207712949 hasPrimaryLocation W32077129491 @default.
• W3207712949 hasRelatedWork W195067670 @default.
• W3207712949 hasRelatedWork W1998259048 @default.
• W3207712949 hasRelatedWork W2072795933 @default.
• W3207712949 hasRelatedWork W2109007021 @default.
• W3207712949 hasRelatedWork W2416541569 @default.
• W3207712949 hasRelatedWork W2887214816 @default.
• W3207712949 hasRelatedWork W3158730239 @default.
• W3207712949 hasRelatedWork W3195917811 @default.
• W3207712949 hasRelatedWork W3207712949 @default.
• W3207712949 hasRelatedWork W4235503789 @default.
• W3207712949 hasVolume "16" @default.
• W3207712949 isParatext "false" @default.
• W3207712949 isRetracted "false" @default.
• W3207712949 magId "3207712949" @default.
• W3207712949 workType "article" @default.